Cofetuzumab pelidotin
Cofetuzumab Pelidotin is an investigational antibody-drug conjugate (ADC) targeted for the treatment of certain types of cancer. It is designed to deliver a potent chemotherapy agent directly to cancer cells that express a specific protein, P-cadherin, on their surface. By targeting P-cadherin-expressing cells, Cofetuzumab Pelidotin aims to minimize the impact on healthy cells, potentially reducing the side effects associated with traditional chemotherapy treatments.
Mechanism of Action[edit | edit source]
Cofetuzumab Pelidotin consists of three main components: an antibody specific to P-cadherin, a linker, and a cytotoxic (cell-killing) agent. The antibody component binds to P-cadherin on the surface of cancer cells. Once bound, the entire complex is internalized by the cell, whereupon the linker is cleaved, releasing the cytotoxic agent. This agent then induces cell death, primarily through the mechanism of apoptosis (programmed cell death).
Clinical Trials[edit | edit source]
As of the last update, Cofetuzumab Pelidotin is undergoing clinical trials to evaluate its safety and efficacy in treating various cancers, including but not limited to, breast cancer, pancreatic cancer, and lung cancer. These trials are crucial for determining the optimal dosing, understanding potential side effects, and evaluating the overall benefit-risk profile of the treatment.
Potential Side Effects[edit | edit source]
Like all cancer therapies, Cofetuzumab Pelidotin may cause side effects. The nature and severity of these side effects can vary depending on individual patient factors, the dosage, and the type of cancer being treated. Common side effects associated with antibody-drug conjugates include, but are not limited to, nausea, fatigue, hair loss, and neutropenia (a decrease in neutrophils, a type of white blood cell).
Future Directions[edit | edit source]
Research is ongoing to further understand the potential of Cofetuzumab Pelidotin in cancer therapy. This includes exploring its use in combination with other treatments, such as immunotherapy and traditional chemotherapy, to enhance its efficacy and possibly expand its indications to other P-cadherin expressing tumors.
See Also[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
